NCT03218072View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 4, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
B-cell Lymphomas
Interventions
DRUG

HLX01

a potential rituximab biosimilar

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY

NCT03218072 - A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas | Biotech Hunter | Biotech Hunter